1. Home
  2. GH vs AGO Comparison

GH vs AGO Comparison

Compare GH & AGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • AGO
  • Stock Information
  • Founded
  • GH 2011
  • AGO 2003
  • Country
  • GH United States
  • AGO Bermuda
  • Employees
  • GH N/A
  • AGO N/A
  • Industry
  • GH Medical Specialities
  • AGO Property-Casualty Insurers
  • Sector
  • GH Health Care
  • AGO Finance
  • Exchange
  • GH Nasdaq
  • AGO Nasdaq
  • Market Cap
  • GH 4.9B
  • AGO 4.1B
  • IPO Year
  • GH 2018
  • AGO 2004
  • Fundamental
  • Price
  • GH $61.40
  • AGO $82.54
  • Analyst Decision
  • GH Strong Buy
  • AGO Buy
  • Analyst Count
  • GH 16
  • AGO 2
  • Target Price
  • GH $57.50
  • AGO $98.50
  • AVG Volume (30 Days)
  • GH 3.4M
  • AGO 347.4K
  • Earning Date
  • GH 07-30-2025
  • AGO 08-07-2025
  • Dividend Yield
  • GH N/A
  • AGO 1.68%
  • EPS Growth
  • GH N/A
  • AGO N/A
  • EPS
  • GH N/A
  • AGO 9.06
  • Revenue
  • GH $828,849,000.00
  • AGO $891,000,000.00
  • Revenue This Year
  • GH $23.36
  • AGO N/A
  • Revenue Next Year
  • GH $21.43
  • AGO N/A
  • P/E Ratio
  • GH N/A
  • AGO $9.10
  • Revenue Growth
  • GH 28.74
  • AGO 3.01
  • 52 Week Low
  • GH $20.14
  • AGO $74.09
  • 52 Week High
  • GH $62.81
  • AGO $96.50
  • Technical
  • Relative Strength Index (RSI)
  • GH 72.00
  • AGO 48.40
  • Support Level
  • GH $57.41
  • AGO $80.14
  • Resistance Level
  • GH $59.92
  • AGO $81.85
  • Average True Range (ATR)
  • GH 2.54
  • AGO 1.46
  • MACD
  • GH 0.99
  • AGO -0.10
  • Stochastic Oscillator
  • GH 92.69
  • AGO 37.37

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About AGO Assured Guaranty Ltd.

Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.

Share on Social Networks: